A Weight Neutral Oral Antidiabetic Drug Would Earn a 25 Percent Patient Share in the Type 2 Diabetes Drug Market

Advantages in Efficacy and Safety Will Make Liraglutide the New Clinical
Gold Standard Drug by 2011, According to a New Report from Decision
Resources

WALTHAM, Mass., July 1 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms focusing on pharmaceutical and
healthcare issues, finds that a weight neutral oral antidiabetic drug would
earn a 25 percent patient share in the treatment of type 2 diabetes,
according to surveyed primary care physicians. Given the prices set for
each of the drug profiles and the size of the type 2 diabetic patient
population in 2011, a 25 percent patient share would result in sales of
$4.1 billion for an agent fitting the report's Minimal Acceptable drug
profile and $8.1 billion for an agent fitting the report's Major
Achievement profile.

The new report entitled Type 2 Diabetes: Blockbuster-Bound Januvia
Addresses Physicians' Concern over Hypoglycemia also finds that Novo
Nordisk's liraglutide will become the new Decision Resources' proprietary
clinical gold standard for the treatment of type 2 diabetes by 2011 as
surveyed primary care physicians indicate that liraglutide has competitive
advantages in terms of efficacy and safety in comparison to the current
gold standard, metformin. Although liraglutide has disadvantages in the
area of delivery because of its subcutaneous injectable formulation, its
positive efficacy and safety attributes offset its disadvantage in
delivery.

"Interviewed primary care physicians also state that liraglutide offers
a considerable advantage over other current and emerging type 2 diabetes
therapies in terms of weight loss," said Donny Wong, Ph.D., principal
analyst at Decision Resources. "As a result, we forecast liraglutide to
become the clinical gold standard among the agents covered in our
analysis."

About the Report

Type 2 Diabetes: Blockbuster-Bound Januvia Addresses Physicians'
Concern over Hypoglycemia is a DecisionBase 2008 report from Decision
Resources. DecisionBase 2008 combines market forecasts with clinical and
commercial end points to assess market share projections in 35 indications.
These outputs are driven by quantitative and qualitative primary research.
DecisionBase 2008 provides detailed market share, patient share, and
price-per-day projections for emerging drugs in development. The market
share projections are based on prescriber surveys that compare physicians'
expectations of a potential target product profile with an emerging product
profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members
of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader
in market research publications, advisory services and consulting designed
to help clients shape strategy, allocate resources and master their chosen
markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.



Elizabeth Marshall
Decision Resources
781-296-2563
emarshall@dresources.com

See Also:

• Holistic Health Supplements – What You Should Know



• Vegetarian Diet and Its Advantages on Health



• Nordic Naturals Professional Sales Division Offers Targeted Nutritional Support for Eyes with ProDHA Eye



• Your Guide To Organic Food



• SheKnows Editorial Initiative: When Autism Is Family

[Via Healthcare]